glp 1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research Trends in the Development of

Injection site reactions occur in 14% of users, typically presenting as mild redness, itching, or temporary discomfort at the injection location

Without amylin, inappropriate glucagon release after eating can happen, which then increases your blood sugar even more

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made